Supplementary Figure 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + &lt;sup&gt;131&lt;/sup&gt;Iodine—Tositumomab